Eton Pharmaceuticals, Inc. (ETON) vs Rapport Therapeutics, Inc. Common Stock (RAPP)
A side-by-side comparison of Eton Pharmaceuticals, Inc. and Rapport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ETON
Eton Pharmaceuticals, Inc.
$54.80HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
RAPP
Rapport Therapeutics, Inc. Common Stock
$31.07HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — ETON vs RAPP
growth of $100 · dividends reinvested · last 2yETON +1428.0% (+290.9%/yr)RAPP +54.8% (+24.4%/yr)ETON compounded faster over this window
Log scale — wide-divergence pair
ETON RAPP
ETON vs RAPP: by the numbers
- •ETON is the larger company ($1.50B vs $1.49B market cap).
- •ETON is profitable (12.02% net margin) while RAPP runs a net loss (-685.80%).
Metrics side by side
Valuation
| Metric | ETON | RAPP |
|---|---|---|
| P/E ratio | 142.49 | N/A |
| Forward P/E | 50.39 | N/A |
| P/S ratio | 14.22 | 74.29 |
| P/B ratio | 32.22 | 3.51 |
| EV / EBITDA | 72.10 | N/A |
| FCF yield | 0.98% | N/A |
Profitability
| Metric | ETON | RAPP |
|---|---|---|
| Gross margin | 57.87% | 0.00% |
| Operating margin | 0.09% | 0.00% |
| Net margin | 12.02% | -685.80% |
| ROE | 27.24% | -32.43% |
| ROIC | 20.41% | -35.66% |
Growth (annualized)
| Metric | ETON | RAPP |
|---|---|---|
| Revenue CAGR (5Y) | 47.98% | N/A |
| Total return CAGR (5Y) | 63.04% | N/A |
Frequently asked
- Is ETON or RAPP more profitable?
- ETON runs the higher net margin — ETON at 12.02% versus RAPP at -685.80%.
Go deeper
Dig into the metrics
Eton Pharmaceuticals P/E ratioEton Pharmaceuticals ROERapport Therapeutics, Inc. Common Stock ROEEton Pharmaceuticals operating marginRapport Therapeutics, Inc. Common Stock operating marginEton Pharmaceuticals revenue growthRapport Therapeutics, Inc. Common Stock revenue growthEton Pharmaceuticals free cash flowRapport Therapeutics, Inc. Common Stock free cash flow
Eton Pharmaceuticals & Rapport Therapeutics, Inc. Common Stock appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.